Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 213407, 16 pages
Review Article

Tibetan Medicine: A Systematic Review of the Clinical Research Available in the West

Institute for Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin, 10098 Berlin, Germany

Received 12 December 2012; Revised 17 February 2013; Accepted 18 February 2013

Academic Editor: Myeong Soo Lee

Copyright © 2013 K. Philip Reuter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Little is known about Tibetan medicine (TM), in Western industrialized countries. Objectives. To provide a systematic review of the clinical studies on TM available in the West. Data Sources. Seven literature databases, published literature lists, citation tracking, and contacts to experts and institutions. Study Eligibility Criteria. Studies in English, German, French, or Spanish presenting clinical trial results. Participants. All patients of the included studies. Interventions. Tibetan medicine treatment. Study Appraisal and Synthesis Methods. Included studies were described quantitatively; their quality was assessed with the DIMDI HTA checklist; for RCTs the Jadad score was used. Results. 40 studies from 39 publications were included. They were very heterogeneous regarding study type and size, treated conditions, treatments, measured outcomes, and quality. Limitations. No Russian, Tibetan, or Chinese publications were included. Possible publication bias. Conclusions. The number of clinical trials on TM available in the West is small; methods and results are heterogeneous. Implications of Key Findings. Higher quality larger trials are needed, as is a general overview of traditional usage to inform future clinical trials. Systematic Review Registration Number. None.

1. Background

Traditional Tibetan medicine (TM), sometimes called “Lamaist” or “Buddhist” medicine, has developed in 1200 years into a unique medical system [13]. In TM, disease is understood as an imbalance of the three “Nyes-pa” (principles) consisting of one or two elements: “rLung” (air, wind), “mKhris-pa” (fire), and “Bad kann” (earth and water) [4]. Buddhist philosophy as well as shamanic origins of Tibetan culture form a background of cosmological, mind-body, and spiritual dimensions [13]. Treatment may consist of medicines (usually preparations of plants [5], seldom minerals or animals), physical treatments (e.g., massage, baths), life and diet regulation, or spiritual techniques [4]. Standardization of the originally individualized medicines, separation from the underlying philosophies, and discontinuation of some techniques (e.g., Tibetan dental medicine, cauterization) have led to derivative forms of TM [6]. We will use the term “Tibetan medicine” for the traditional TM (with its individual life style advice, diet, physical, and spiritual means) as well as larger or smaller subsets or varieties of it, down to single formulas.

Besides the regions of the historical Tibet, very similar medical traditions are practised since the Mongolian conquest of Tibet in the 13th century in Mongolia, adjacent Siberia, and in the Russian province Kalmykia (Figure 1) [7]. Especially with traditional Mongolian medicine, TM has a substantial similarity. TM use in Western industrialized countries (the “West”) originates in a line of descendants of a Buryat physician migrating westward in the 19th century (Figure 1) [8, 9]. Still, there is little awareness of TM in the general Western public. Following the rising interest in traditional Chinese medicine (TCM) and complementary or alternative medicine (CAM) in general, more demand from Western countries can be expected in the future. The amount of available research in the West is small. A Medline search up to December 31, 2010, for example, for “Tibetan medicine” returned 371 hits, 0.0183 times the number for “traditional Chinese medicine.” The existing literature indicates a palliative, possibly curative potential, especially for chronic diseases [10], but studies on its multimodal individualized approach are scarce and systematic reviews exist only for one TM product [1115]. Therefore, we attempted to present in this paper a systematic overview of clinical research currently available in the West on Tibetan medicine, and aim to provide details on methods and study quality. Some preliminary data can be found in [16].

Figure 1: Tibetan medicine in geography and history. Map based on [7, 8, 1722].

2. Methods

A preliminary list of 15 literature databases was tested using the search terms “Tibetan medicine,” “Himalaya medicine,” “Tibetan herbal,” and “Lamaistic medicine.” The database list had been compiled from recommendations by experts, by Ovid [23], and by Deutsches Institut für Medizinische Dokumentation und Information (DIMDI) [24]. Those returning the most hits were used for the literature search, together with databases that were recommended by experts or appeared relevant in their characterization on the websites of DIMDI or the Charité library [25]. We finally searched seven databases up to publication date December 31, 2010: ABIM (accessed via Rijksuniversiteit Groningen), AMED (DIMDI), CAMbase (cambase), CCmed (DIMDI), Cochrane Collaborative Library (OVID), Embase (OVID), and Medline (PubMed). The search term “(Tibet OR Himalaya OR Mongolia OR Buddhist) AND (herbal OR medicine) AND study” was adapted as necessary to database language and syntax. Similar searches were used on the medical information services of DIMDI [24] and ZB MED [26] and by adding “AND clinical study” on Google scholar [27]. The published literature lists [28, 29] were screened. We also contacted European experts, research departments of TM medical faculties (Mentsekhang) in Lhasa and Dharamsala, and European centres for TM [3032]. All identified literature was further screened for relevant citations. Duplicate references were eliminated throughout the process; of multiple publications of a study the most recent one was included. Included papers had to be written in English, German, French, or Spanish and had to present clinical trial results on a clinical outcome. No further restrictions were applied.

One of the authors (K. P. Reuter) used a predefined form to extract descriptive study data into MS Access 2003 and MS Excel 2003 [33, 34] data bases, including bibliographic data, and study parameters such as type, methods (including diagnostics, randomization, and blinding), and patient numbers. Furthermore, data regarding treated diseases, interventions, outcomes, and types of outcome measures (clinical symptoms, tests, and laboratory parameters) were extracted. If no primary outcome was defined, the first outcome mentioned in the title or the abstract was extracted, unclear cases were discussed with another author (C. M. Witt) until consensus was reached.

Methodological quality of the studies was determined with a DIMDI checklist (Table 1) that is used to evaluate studies for in-/exclusion in health technology assessments (HTA) in Germany [35]. The checklist has up to 31 items sorted into 7 categories and was used on a descriptive basis. Randomized controlled trials (RCTs) were further evaluated with the Jadad score [36, 37]. Descriptive statistics were calculated using MS Access 2003 and MS Excel 2003 [33, 34].

Table 1: DIMDI HTA checklist items.

3. Results

From 1383 screened records, we identified 40 studies reported in 39 publications (one contains 2 studies [38]), see Figure 2. An additional search without the terms “herbal,” “Buddhist,” and “Mongolian” did not result in fewer relevant publications. Thirty-five of the publications were journal articles, two were book chapters, and one is treated in this paper as a single Internet publication, although different findings had been published in several online media reports [39]. Only 18 publications were found by the initial data base searches. Most of the others were indeed indexed, as a reverse search (for already known publications) revealed. Written in English were 53.8% ( ) of the publications, the other 46.2% (18) were in German. Most publications came from Poland and Switzerland (30.8% or each, all on products of Padma AG). The Asian studies were from India (15.4%, ) or China (5.1%, ). The earliest publication appeared in 1970. Since 1990 every 5 years about 3 new RCTs were published and, less evenly distributed, most of the observational studies (total ). The 5 nonrandomized controlled trials were published between 1986 and 1991, and the 6 case studies or case series in 1998 or later (Table 2). The setting of 7 studies (17.5%) was multicentred [4046]. Four studies (10.0%) were retrospective [40, 45, 47, 48].

Table 2: Included studies.
Figure 2: The literature search. References from indexing services were collected first, then other sources were added.

In the RCTs included were 2028 patients, 1020 of them received the Tibetan medicine treatment. Study duration ranged from 14 days to 12 months (mean = 114 days). Most RCTs investigated Padma 28 ( ) (the first study in [38], and [4956]) or Padma Lax ( ) [57]. A whole medical system approach with a complex traditional TM intervention was applied in 3 studies on diabetes mellitus [43], arthritis, [58] or hepatitis B [59]. Tibetan yoga in lymphoma patients [60] and a single TM preparation (Zhi Byed 11) for postpartum haemorrhage [44] were each the subject of 1 RCT. One study [61] was declared an RCT but lacked randomization.

From those publications including herbal medicines, four did not provide details on the used medication [42, 58, 59, 62], two provided the name of the preparations but not the ingredients [43, 48], and two provided the name of the preparation and ingredients, but no information on the quantity of the ingredients [44, 63]. Data on both ingredients and their quantity was only available for Padma 28 and Padma Lax.

The duration of the non-randomized controlled trials was between 6 weeks and 6 months (mean = 43 d), 54% of the 678 patients received the verum Padma 28. Four non-randomized controlled trials included children with chronic respiratory tract infections [46, 64, 65] or juvenile arthritis [66]. One trial on adults included angina pectoris patients [61].

In the observational studies included, there were 1824 patients. The observation duration ranged from 15 days to 2 years (mean = 217 days). In some of the publications, the study duration was not clearly stated (the second study in [38], and [41]) or varied between participants [42, 45, 63]. Seven observational studies investigated Padma 28 (the second study in [38], and [47, 6771]). One study each investigated Padma Lax [41] or a jewel pill (Byu-Dmar 13) [63]. Complex TM treatment was applied in 5 studies [39, 42, 45, 48, 62].

The duration of the case studies/series ranged widely from several days to 13.5 years [40]. Padma 28 was investigated in 4 case studies [40, 7274], Padma Lax in 1 [75], and complex TM in another [76].

All studies included a total of 4684 patients, ranging from 1 to 967 per trial (mean = 117, SD = 187). Ten studies did not state the patients’ sex ( , 35.2% of all patients in the present review) [4042, 47, 56, 63, 65, 67, 71, 77]. From the other studies, 1080 patients (23.1%) were male and 1956 (41.8%) female. Data on age was available in 31 of 39 studies. Children (age 10 months to 16 years, ) only were included in 5 studies [46, 64, 65, 70, 71]. Only 2 studies reported on ethnicity (Tibetan patients in both) [42, 58]. In 32 studies, dropouts were reported ranging from 0% (15 studies) to 53% [45] with a mean dropout rate of 15%. In 21 of the 28 trials of Padma 28 or Padma Lax, the mean drop out rate was 6%.

The checklist results for quality assessment are presented at item level in Table 3 for each study. Depending on study type and setting, 10 to 26 items could be answered. Had the assessment been for HTA purposes, only 1 case study [76] and 1 RCT [55] would have been eligible for inclusion in a HTA. Ignoring only one item (G2, provision of confidence intervals) would have raised that number to 13, including 8 RCTs that the Jadad score rated as good or very good quality. The Jadad score of the 15 RCTs (Table 4) reached a mean SD of (median = 4). Randomization scored (median = 1), blinding (median = 2), and drop-out reporting (median = 1). Studies on Padma 28 or Padma Lax had higher Jadad scores than studies on other treatments: (median = 4) versus (median = 2).

Table 3: DIMDI HTA checklist results.
Table 4: Jadad Score Results for Included RCTs.

All studies followed conventional “Western” medical diagnoses. Additional traditional TM diagnostics were recorded in 11 studies that investigated the traditional multimodal treatment. In 9 of them, the Tibetan diagnosis was used to plan the therapy [39, 42, 43, 45, 48, 58, 59, 62, 76].

Thirty studies including 3497 patients (74.7% from all included studies) investigated single formulations: Padma 28 ( studies), Padma Lax (3), Byu-Dmar 13 (1), and Zhi Byed 11 (1). The complex traditional Tibetan treatment was studied in 9 trials that included a total of 1140 (24.3%) patients. Here, and in the Padma 28 studies, the treated conditions varied widely. For example, Padma 28 was investigated for arteriosclerosis, infections, neurological disorders, venous insufficiency, arthritis, and hypercholesteraemia.

Assessed outcomes included clinical outcomes such as symptom scales ( studies), laboratory tests (19), clinical tests (such as ankle/brachial pressure index, blood pressure, or weight; 9), and other (9), such as microbiology, histology, or the need for conventional medication. The authors drew positive conclusions on their data in 34 studies. In 2 RCTs, TM was found to be inferior to conventional medicine, but better than placebo [44, 46]. In one study, only 1 of 5 outcomes improved [60]; in 2 studies the primary outcome did not change significantly while secondary outcomes did [42, 52]. The comparison of the traditional and a not further specified “special” Tibetan medicine [59] resulted in comparable clinical improvements. The remaining studies found no significant differences to controls [49, 65], or their authors were doubtful about the observed effects [39]. Statements about adverse effects were included in 23 studies, in 11 of them no adverse effects were reported, and 2 studies did not mention the number of patients with adverse effects [39, 53]. The remaining 10 studies reported adverse effects with a range from 5% to 55% of the patients.

Some disease groups were researched in several trials. Peripheral arterial occlusive disease was treated with Padma 28 in 9 studies (6 RCTs, (the first study in [38], [5155])) 1 observation study, (the second study in [38]) and 2 case studies [40, 72]. Maximum walking distance increased in 5 studies (the first study in [38], and [51, 5355]). Both case studies and the observational study reported a general clinical improvement. The ankle/brachial pressure index in 1 RCT [52] was unchanged. All authors made a positive conclusion regarding Padma 28.

Five studies (3 non-randomized controlled trials [46, 53, 65] and 2 observation studies [70, 71]) investigated Padma 28 for recurrent respiratory tract infections in children. Improvements were seen for frequency of infections [70, 71] or spontaneous bacterial activity [64]. In 1 of the controlled trials, no significant difference to standard therapy was found [65], and in another study, inferiority to other therapies was reported [46].

Osteoarthritis or rheumatoid arthritis was treated in three trials: 1 RCT [58] and 1 observational study [62] with the traditional multimodal approach, and with Padma 28 in 1 controlled trial [66]. All studies reported pre-/post-improvements or superiority to controls regarding symptom severity.

Padma Lax in chronic constipation was the subject of three studies (1 RCT [57], 1 controlled trial [75], and 1 observational study [41]). All reported clinical improvements.

In 3 other trials, hepatitis B patients were either treated with a “special” TM (that was not further specified) in comparison to traditional TM (1 RCT [59]) or with Padma 28 (2 observational studies [47, 69]). All publications reported positive results for laboratory outcomes. The comparison of traditional and “special” traditional TM found comparable improvements but did not achieve seroconversions.

4. Discussion

In this paper, we presented an overview of the clinical research on traditional Tibetan medicine (TM) that is currently available in the West. Three quarters of the included studies tested single formulations, most of them products of a single company. One quarter investigated the traditional multimodal TM approach. Studies were very heterogeneous regarding study type and size, treated conditions, treatments, measured outcomes, and quality.

In this, to our knowledge, first systematic overview of clinical TM research available in the West, we tried to minimize subjectivity using pre-defined systematic methods wherever possible (data extraction sheets, established quality assessment tools). However, the small number of trials scattered over a whole medical system and very heterogeneous treated diseases prohibited more formal or in-depth analyses.

Despite the broad literature search, some studies may not have been identified, for various reasons. Although Mongolian and Tibetan medicine are not completely identical, we have included “mongolian” in the search terms in order to find as much relevant literature as possible. We did not search for single TM interventions such as bathing or bloodletting and assumed that they are well covered under the umbrella term “medicine.” Although we detected with this search a study on Tibetan yoga [60], we possibly missed other studies. Furthermore, publication bias could have had occurred, as some papers [11, 15, 58] indicated the existence of studies that have not been published (or at least not in indexed journals) [7782]. Several papers were not identified by our search strategy in the literature databases, but could have been found searching for “Padma 28” or “Padma Lax.” Clearer labelling of TM studies in the future would be helpful. On the other hand, our search seems to have been partly redundant, as all identified publications could have been found with fewer search terms. The main limitation is that our language restriction excluded articles in Russian, Tibetan, and Chinese. This literature was not accessible for us. Furthermore, we learned from our field work and from discussions with Western and Chinese manufacturers during an interdisciplinary symposium on TM [16] that most literature on clinical research published in Tibetan is not available in indexed journals and that most research published in Chinese addresses preclinical questions.

The evaluated literature presented a high number of studies without a control group. Only a few single products were subject to in-depth investigation. Both facts indicate an early stage of research in a new and largely unexplored field where only few focused inquiries exist. The predominating countries of origin (>2/3 European) and the 70% of studies on Padma products among the included literature are consequences of the language restrictions of our search as well as of the historical development of TM utilization in the West. Although they are prescribed in a standardized and nonindividualized fashion, the Padma products are a genuine Tibetan medication according to manufacturers, study authors, and independent experts [17, 83, 84]. Adaptation of constituents to local situation and ecology is an accepted practice in TM. It was done in one study when Tibetan physicians reduced the traditional Byu-Dmar 25 by 12 ingredients to comply with Tibetan pharmacopoeia and European regulations, resulting in Byu-Dmar 13 [63]. A similar strategy might have been used in two other studies [39, 62].

The heterogeneous nature of the included studies demanded the use of quality assessment instruments that were suitable for diverse study designs, but have the general disadvantage of allowing only rough estimates of the assessed quality. Nevertheless, they allowed spotting the more obvious deficiencies that are symptomatic of research at an early stage and that future research can avoid with improved methodology on the grounds of evidence-based medicine. Case studies and observational studies are useful to gather information on traditional usage and settings and to identify areas where controlled studies seem promising. Then, to provide higher-level evidence, more RCTs will be needed. Methodological issues such as small samples, insufficiently described populations in many studies, pre-/post-comparisons of treatment within a group, or comparator treatments without clinical relevance all indicate that TM research as seen through the Western literature is still at a nascent stage. Furthermore, the quality of most studies and the heterogeneity of interventions and outcomes make clear conclusions impossible.

5. Conclusion

The clinical research on traditional Tibetan medicine (TM) that is available in Western industrialized countries is scarce and scattered over a whole medical system, but shows interesting results. Better research methodology should be applied, and larger trials are needed, as is a general overview of traditional usage to inform future clinical research.


This work was supported within a grant of the Chair for Complementary Medicine Research, funded by the Karl and Veronica Carstens Foundation, Essen, Germany. The authors state that they have no conflict of interests.


  1. T. Dunkenberger, Das Tibetische Heilbuch, Windpferd Verlagsgesellschaft, Aitrang, Germany, 1999.
  2. P. Skinner, “Tibetan medicine,” in The Gale Encyclopedia of Alternative Medicine, T. Gale, Ed., Longe, Detroit, Mich, USA, 2nd edition, 2005. View at Google Scholar
  3. V. Dash, Tibetan Medicine: Theory and Practice, Sri Satguru Publications, Delhi, India, 1997.
  4. G. Samel, Tibetan Medicine, Little, Brown & Company, London, UK, 2001.
  5. C. M. Witt, N. Berling, N. Thingo, M. Cuomo, and S. N. Willich, “Evaluation of medicinal plants as part of Tibetan medicine—prospective observational study in Sikkim and Nepal,” Journal of Alternative and Complementary Medicine, vol. 15, no. 1, pp. 59–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Asshauer, Tibets Sanfte Medizin: Heilkunst vom Dach der Welt, Oesch, Zürich, Switzerland, 4th edition, 2003.
  7. B. B. Gaitonde and P. N. Kurup, “Regional overview: South-East Asia region,” in WHO Global Atlas of Traditional, Complementary and Alternative Medicine, G. Bodeker, C. Ong, C. Grundy et al., Eds., pp. 75–82, World Health Organisation, Centre for Human Development, Kobe, Japan, 2005. View at Google Scholar
  8. H. Schwabl, S. Geistlich, and E. McHugh, “Tibetische Arzneimittel in Europa: Historische, praktische und regulatorische Aspekte,” Forschende Komplementärmedizin, vol. 13, supplement 1, pp. 1–6, 2006. View at Google Scholar
  9. V. Badmaev Jr., “The continuation of the Badmaev family tradition in its 5th generation,” AyurVijnana, vol. 7, 2000. View at Google Scholar
  10. R. Saller, “Tibetische Heilmittel bei chronischen Erkrankungen, Einleitung,” in Tibetische Heilmittel bei Chronischen Erkrankungen, Zürich, Switzerland, 2005. View at Google Scholar
  11. J. Melzer, R. Brignoli, C. Diehm et al., “Treating intermittent claudication with Tibetan medicine Padma 28: does it work?” Atherosclerosis, vol. 189, no. 1, pp. 39–46, 2006. View at Publisher · View at Google Scholar
  12. V. Badmaev, “Medicine tested by Science: an effective botanical treatment for circulatory deficience due to atherosclerosis,” Nutri-Cosme-Ceutici,, Rome, Italy, 2002.
  13. F. Ueberall, D. Fuchs, and C. Vennos, “Das anti-inflammatorische Potential von Padma 28: Übersicht experimenteller Daten zur antiatherogenen Wirkung und Diskussion des Vielstoffkonzepts,” Forschende Komplementärmedizin, vol. 13, supplement 1, pp. 7–12, 2006. View at Google Scholar
  14. A. Weseler, R. Saller, and J. Reichling, “Comparative investigation of the antimicrobial activity of Padma 28 and selected European herbal drugs,” Forschende Komplementärmedizin und Klassische Naturheilkunde, vol. 9, no. 6, pp. 346–351, 2002. View at Google Scholar
  15. M. B. Röösli, Systematische Übersichtsarbeit: Klinische Studien zur Wirksamkeit und Sicherheit des phytotherapeutischen Kombinationspräparats PADMA 28, Universität Zürich, Zürich, Switzerland, 2009.
  16. C. M. Witt, S. Craig, and M. Cuomu, Tibetan Medicine Research—From Current Evidence to Future Strategies: Advice from an Interdisciplinary Conference, KVC Verlag, Essen, Germany, 2012.
  17. S. Geistlich and H. Schwabl, “Von der Tradition zur ‘evidence-based medicine’,” Schweizerische Zeitschrift für Ganzheitsmedizin, vol. 15, pp. 133–140, 2003. View at Google Scholar
  18. B. Gerke, “Tradition and modernity in Mongolian medicine,” The Journal of Alternative and Complementary Medicine, vol. 10, no. 5, pp. 743–749, 2004. View at Google Scholar
  19. E. M. Plakun, “Psychiatry in Tibetan Buddhism: madness and its cure seen through the lens of religious and national history,” The Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, vol. 36, no. 3, pp. 415–430, 2008. View at Publisher · View at Google Scholar
  20. M. Saxer, Journeys with Tibetan medicine [M.S. thesis], 2004,
  21. I. A. Navchoo and G. M. Buth, “Medicinal system of Ladakh, India,” Journal of Ethnopharmacology, vol. 26, no. 2, pp. 137–146, 1989. View at Publisher · View at Google Scholar
  22. United Nations, “World, Map No. 4170,” October 2006,
  23. Wolters Kluwer, Ovid Technologies, 2010,
  24. DIMDI, Datenbanken A-Z, 2010,
  25. Bibliothek der Charité, Datenbanken, 2010,
  26. ZB MED, MedPilot, 2010,
  27. Google, Google Scholar, 2010,
  28. A. G. Padma, Padma 28—Literaturverzeichnis 2/09, 2009,
  29. J. Aschoff, Tibetische Medizin—Kommentierte Bibliographie, Fabri, Ulm, Germany, 1996.
  30. Institut für Ost-West-Medizin, Kursreihe Einführung in die Tibetische Medizin, 2008,
  31. Interessengemeinschaft Tibetische Medizin, Programm im Detail: der Ausbildung zur Therapeutin tibetische Medizin, Interessengemeinschaft Tibetische Medizin, 2011,
  32. New Yuthog Institute, 4 year Tibetan Medicine course, 2011,
  33. Access, Microsoft, Redmond, Wash, USA, 2003.
  34. Excel, Microsoft, Redmond, Wash, USA, 2003.
  35. M. Ekkernkamp, D. Lühmann, and H. Raspe, Methodenmanual für HTA-Schnellverfahren' und exemplarisches Kurz-HTA'. Die Rolle der quantitativen Ultraschallverfahren zur Ermittlung des Risikos für osteoporotische Frakturen, vol. 34, Asgard Verlag, Sankt Augustin, Germany, 2003.
  36. D. Moher, A. R. Jadad, and P. Tugwell, “Assessing the quality of randomized controlled trials. Current issues and future directions,” International Journal of Technology Assessment in Health Care, vol. 12, no. 2, pp. 195–208, 1996. View at Google Scholar
  37. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar
  38. F. Hürlimann, “Eine lamaistische Rezeptformel zur Behandlung der peripheren arteriellen Verschlusskrankheit,” Schweizerische Rundschau Fur Medizin, vol. 67, pp. 1407–1409, 1979. View at Google Scholar
  39. E. Leeman, Y. Dhonden, and M. Woolf, A Phase I Trial of Tibetan Medicine for Advanced Breast Cancer, 2001,
  40. C. Bommeli, R. Bohnsack, and C. Kolb, “Praxiserfahrungen mit einem Vielstoffpräparat aus der tibetischen Heilkunde,” Erfahrungsheilkunde, vol. 50, no. 11, pp. 745–756, 2001. View at Google Scholar
  41. H. Flück and W. P. Bubb, “Eine lamaistische Rezeptformel zur Behandlung der chronischen Verstopfung,” Schweizerische Rundschau für Medizin Praxis, vol. 59, no. 33, pp. 1190–1193, 1970. View at Google Scholar
  42. F. Li, “Ergebnisse der Behandlung von symptomatischen Patienten mit tibetanischer Medizin, die an einer Infektion mit Helicobacter Pylori (HP) leiden,” Deutsche Zeitschrift für Akupunktur, vol. 44, no. 3, pp. 183–185, 2001. View at Publisher · View at Google Scholar
  43. T. Namdul, A. Sood, L. Ramakrishnan et al., “Efficacy of Tibetan medicine as an adjunct in the treatment of type 2 diabetes,” Diabetes Care, vol. 24, no. 1, pp. 175–176, 2001. View at Publisher · View at Google Scholar
  44. S. Miller, C. Tudor, V. Thorsten et al., “Randomized double masked trial of Zhi Byed 11, a Tibetan traditional medicine, versus misoprostol to prevent postpartum hemorrhage in Lhasa, Tibet,” Journal of Midwifery & Women's Health, vol. 54, no. 2, pp. 133.e1–141.e1, 2009. View at Publisher · View at Google Scholar
  45. D. Neshar, “Clinical case Study of Cancer (Dres-ned) patients treated at Men-Tsee-Khang's Bangalore Branch Clinic for the period of 27 month from November 2002 to February 2005,” Journal of Men-Tsee-Khang, vol. 4, no. 1, pp. 50–68, 2007. View at Google Scholar
  46. W. Prusek, A. Jankowski, G. Radomska et al., “Immunostimulation in recurrent respiratory tract infections therapy in children,” Archivum Immunologiae et Therapiae Experimentalis, vol. 35, no. 3, pp. 289-–2302, 1987. View at Google Scholar
  47. W. Brzosko and A. Jankowski, “PADMA 28 bei chronischer Hepatitis B: Klinische und immunologische Wirkungen,” Schweizerische Zeitschrift für Ganzheitsmedizin, vol. 7-8, supplement 1, pp. 13–14, 1992. View at Google Scholar
  48. D. Neshar, “Efficacy of traditional Tibetan medicine against diabetes mellitus,” Journal of Men-Tsee-Khang, vol. 2, no. 2, pp. 25–35, 2000. View at Google Scholar
  49. H. P. Brunner-La Rocca, R. Schindler, M. Schlumpf et al., “Effects of the Tibetan herbal preparation Padma 28 on blood lipids and lipid oxidisability in subjects with mild hypercholesterolaemia,” VASA, vol. 34, no. 1, pp. 11–17, 2005. View at Publisher · View at Google Scholar
  50. T. Korwin-Piotrowska, D. Nocon, A. Stankowska-Chomicz, A. Starkiewicz, J. Wojcicki, and L. Samochowiec, “Experience of Padma 28 in multiple sclerosis,” Phytotherapy Research, vol. 6, no. 3, pp. 133–136, 1992. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Mehlsen, H. Drabaek, J. Petersen et al., “Der Effekt einer tibetischen Kräutermischung (Padma 28) auf die Gehstrecke bei stabiler Claudication intermittens,” Forschende Komplementärmedizin und Klassische Naturheilkunde, vol. 2, no. 5, pp. 240–245, 1995. View at Publisher · View at Google Scholar
  52. S. Sallon, G. Beer, J. Rosenfeld et al., “The efficacy of Padma 28, a herbal preparation, in the treatment of intermittent claudication: a controlled double-blind pilot study with objective assessment of chronic occlusive arterial disease patients,” Journal of Vascular Investigation, vol. 4, no. 3, pp. 129–136, 1998. View at Google Scholar · View at Scopus
  53. L. Samochowiec, J. Wojicki, and K. Kosminder, “Wirksamkeitsprüfung von Padma 28 bei der Behandlung von Patienten mit chronischen arteriellen Durchblungsstörungen,” Polbiopharm Reports, no. 22, pp. 3–14, 1987. View at Google Scholar
  54. R. Schrader, B. Nachbur, and F. Mahler, “Die Wirkung des tibetanischen Kräuterpraparates Padma 28 auf die Claudicatio intermittens,” Schweizerische Medizinische Wochenschrift, vol. 115, no. 22, pp. 752–756, 1985. View at Google Scholar
  55. H. S. Smulski and J. Wojcicki, “Plazebokontrollierte Doppelblindstudie zur Wirkung des tibetanischen Kräuterpräparates Padma 28 auf die Claudication intermittens,” Forschende Komplementärmedizin und Klassische Naturheilkunde, vol. 1, pp. 18–26, 1994. View at Google Scholar
  56. W. Split, M. Szydlowska, and W. Brzosko, “The estimation of the action of Padma-28 in the treatment of ischaemic brain stroke,” European Journal of Neurology, vol. 5, supplement 1, p. 9, 1998. View at Google Scholar
  57. S. Sallon, E. Ben-Arye, R. Davidson et al., “A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula,” Digestion, vol. 65, no. 3, pp. 161–171, 2002. View at Publisher · View at Google Scholar
  58. M. Ryan, “Efficacy of the Tibetan treatment for arthritis,” Social Science & Medicine, vol. 44, no. 4, pp. 535–539, 1997. View at Publisher · View at Google Scholar
  59. R. Sangmo, D. Dolma, T. Namdul et al., “Clinical trial of Tibetan medicine in the treatment of chronic hepatitis B,” Journal of Men-Tsee-Khang, vol. 4, no. 1, pp. 32–49, 2007. View at Google Scholar
  60. L. Cohen, C. Warneke, R. T. Fouladi et al., “Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma,” Cancer, vol. 100, no. 10, pp. 2253–2260, 2004. View at Publisher · View at Google Scholar
  61. J. Wojcicki, L. Samochowiec, and C. Dolata, “Controlled double-blind study of Padma 28 in angina pectoris,” Herba Polonica, vol. 32, no. 2, pp. 107–113, 1986. View at Google Scholar
  62. C. Pauwvliet, “A pilot study on the effect of Tibetan medicine on patients with rheumatic diseases,” in Tibetan Medicine, J. Aschoff and I. Rösing, Eds., pp. 39–49, Fabri, Ulm, Germany, 1997. View at Google Scholar
  63. J. Aschoff, T. Tashigang, and J. Maier, “Clinical trial in migraine prophylaxis with a multicomponent Tibetan jewel-pill. Transfer problems of Tibetan to Western medicine, demonstrated, “pars pro toto” on the Aconite medical plants in our Tibetan prescription,” in Tibetan Medicine,Verlag, J. Aschoff and I. Rösing, Eds., pp. 21–38, Fabri, Ulm, Germany, 1997. View at Google Scholar
  64. S. Jankowski, A. Jankowski, S. Zielinska, M. Walczuk, and W. J. Brzosko, “Influence of Padma 28 on the spontaneous bactericidal activity of blood serum in children suffering from recurrent infections of the respiratory tract,” Phytotherapy Research, vol. 5, no. 3, pp. 120–123, 1991. View at Google Scholar · View at Scopus
  65. H. Mansfeld, “Beeinflussung rezidivierender Atemwegsinfekte bei Kindern durch Immunostimulation,” Therapeutikon, vol. 2, p. 707, 1988. View at Google Scholar
  66. W. J. Brzosko, A. Jankowski, W. Prusek, and H. Ollendiek, “Influence of Padma 28 and the thymus extract on clinical and laboratory parameters of children with juvenile chronic arthritis,” International Journal of Immunotherapy, vol. 7, no. 3, pp. 143–147, 1991. View at Google Scholar · View at Scopus
  67. P. Schleicher, “Wirkung von Padma 28 auf das Immunsystem bei Patienten mit Acquired Immunodeficiency Syndrom im Stadium des Pre-AIDS,” Schweizerische Zeitschrift für Ganzheitsmedizin, vol. 2, p. 58, 1990. View at Google Scholar
  68. F. Füllemann, “Padma 28 in der Behandlung von chronischen Zahnpulpitiden: Eine Praxisbeobachtung an 49 Fällen,” Forschende Komplementärmedizin, vol. 13, supplement 1, pp. 28–30, 2006. View at Google Scholar
  69. A. Gladysz, J. Juszczyk, and W. J. Brzosko, “Influence of Padma 28 on patients with chronic active hepatitis B,” Phytotherapy Research, vol. 7, no. 3, pp. 244–247, 1993. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Jankowski, E. Drabik, Z. Szysko et al., “Die Behandlung rezidivierender Atemwegsinfektionen bei Kindern durch Aktivierung des Immunsystems,” Therapiewoche Schweiz, vol. 2, no. 1, pp. 25–32, 1986. View at Google Scholar
  71. A. Jankowski, R. Jankowska, and W. Brzosko, “Behandlung infektanfälliger Kinder mit Padma 28,” Schweizerische Zeitschrift für Ganzheitsmedizin, vol. 7-8, supplement 1, pp. 22–23, 1992. View at Google Scholar
  72. S. Feldhaus, “Ganzheitliches Therapiekonzept bei pAVK,” Schweizerische Zeitschrift für Ganzheitsmedizin, vol. 16, p. 72, 2004. View at Google Scholar
  73. M. Günsche, “Therapieresistenz bei Tagesmüdigkeit, Antriebsschwäche und Konzentrationsschwierigkeit,” Schweizerische Zeitschrift für Ganzheitsmedizin, vol. 17, p. 90, 2005. View at Google Scholar
  74. J. Rüttgers, “Crux medicorum: das offene Bein,” Schweizerische Zeitschrift für Ganzheitsmedizin, vol. 16, pp. 278–280, 2004. View at Google Scholar
  75. S. Feldhaus, “Behandlung der chronischen Obstipation eines tetraplegischen Patienten mit dem tibetischen Arzneimittel Padma Lax—ein Fallbericht,” Forschende Komplementärmedizin, vol. 13, supplement 1, pp. 31–32, 2006. View at Publisher · View at Google Scholar
  76. S. Changbar, “Tibetan medicine in the treatment of aplastic anaemia,” AyurVijnana, vol. 4, 1998. View at Google Scholar
  77. M. Ryan, “Measuring the efficacy of Tibetan treatment for acute hepatitis,” in Proceedings of the 10th Annual Conference on Ethnic Culture and Folk Knowledge of Russian Acadamy of Sciences, Moscow University Press, Moscow, Russia, 1994.
  78. S. Sommogy and P. Schleicher, “Therapie der peripheren arteriellen Verschlusskrankheit (PAVK) mit Padma 28,” Bericht 26.6, Abteilung für Gefäßchirurgie, Technische Univerität München und Zytognost GmbH, München, Germany, 1990.
  79. L. Samochowiec, J. Wojcicki, K. Kosmider et al., “Wirksamkeitsprüfung von Padma 28 bei der Behandlung von Patienten mit chronischen arteriellen Durchblutungsstörungen,” Herba Polonica, vol. 33, pp. 29–41, 1987. View at Google Scholar
  80. K. Winther, A. Kharazmi, H. Himmelstrup, H. Drabaek, and J. Mehlsen, “PADMA-28, a botanical compound, decreases the oxidative burst response of monocytes and improves fibrinolysis in patients with stable intermittent claudication,” Fibrinolysis, vol. 8, no. 2, pp. 47–49, 1994. View at Google Scholar · View at Scopus
  81. H. Panjwani and W. Brzosko, “Influence of selected immunocorrecting drugs on intellectual function of the brain due to arteriosclerosis,” Nowiny Lekarskie, vol. 5, pp. 665–670, 1998. View at Google Scholar
  82. J. Hasik, H. Klinkiewicz, K. Linke et al., “Effectiveness of duodenal ulcer disease treatment by PADMA 28,” Nowiny Lekarskie, vol. 2, pp. 40–44, 1992. View at Google Scholar
  83. T. Kalsang, Interview with KPR [pers. comm.], Dharamsala, India, October 2008.
  84. T. Tamdin, “Challenges and prospects of research in Tibetan medicine,” in Tibetische Heilmittel bei Chronischen Erkrankungen, Zürich, Switzerland, November 2005. View at Google Scholar